During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Discover the latest updates to the EAU guidelines for muscle-invasive and metastatic bladder cancer in 2025. Learn more.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...

A new cancer detection test to analyze volatile organic compounds through urine analysis, was granted the Breakthrough Device Designation status by the U.S. FDA. The system, which is built on gas ...

Invasive bladder cancer can be treated through immunotherapy involving Bacillus Calmette-Guérin (BCG), but some 40%-60% of ...

DNA profiling can help stratify risk of recurrence in patients with BCG-unresponsive NMIBC treated with atezolizumab. Read ...

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...